Kodiak Sciences is trading at $94.72, down 4.57%, with biotech-sector weakness a possible contributor to the decline.
- XBI fell 2.01% during the regular session; Kodiak’s decline was steeper, so sector pressure may not fully explain it.
- No clear company-specific announcement was found to explain the October 13 decline.
- Positive DAYBREAK trial coverage and an analyst price-target increase predate the session and do not explain the drop.